Daniela Couto

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

Citryll BV is a private pharmaceutical company located in Oss, the Netherlands, at the Pivot Park. Citryll is dedicated to developing and commercializing therapeutics that target netosis and NETs, with a focus on immune-mediated inflammatory diseases. The Dutch company's lead antibody, Cit-013, has a unique dual mode of action and proprietary NET biomarker assays, making it a promising drug for rheumatoid arthritis and hidradenitis suppurativa. The initial clinical trials with Cit-013 are expected to provide the foundation for a new treatment paradigm for immune-mediated inflammatory diseases. The company was founded in 2015 by Helmuth van Es, Renato Chirivi, and the late Jos Raats of ModiQuest.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.

Complement Therapeutics Ltd. develops medicines that target the complement system. The British company was founded by Richard Unwin, Simon J. Clark, and Paul Bishop. The CEO is Rafiq Hasan.

Biogeneration Management is a venture capital firm, a subsidiary of BioGeneration Holding BV and was founded in 2006. Biogeneration management is headquartered in Naarden.